01 / DESIGN
What was studied?
GLORY-1 randomized 610 adults in China to mazdutide or placebo for 48 weeks. The two primary weight endpoints were evaluated at week 32.
02 / FINDINGS
What did the researchers report?
Both mazdutide groups showed greater average weight reduction than placebo at the primary assessment, with further results reported at week 48. Gastrointestinal events were the most frequent adverse effects.
03 / LIMITS
How should it be interpreted?
Eligibility used the study's BMI thresholds and related conditions. These results should not be generalized without considering population differences, and the paper does not certify research-supply product quality or clinical suitability.
Voltera Peptide editorial reading note. Based on the linked source record. Methods and corrections.